SBT6290
As of the edition of 20 October 2026, SBT6290 is a drug known only by a code name: stopped in 2022; acts on NECTIN4.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2022
- Kind
- Code name only
- Registered trials
- 1, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NECTIN4 | Nectin-4 | Q96NY8 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Silverback Therapeutics | Lead sponsor of trials | 2022 to now |